Blab Business
Viking Therapeutics (VKTX) Investor Outlook: No Revenue, Obesity Drug in Phase 2
Viking Therapeutics Inc. (NASDAQ: VKTX) is a small‑cap biotechnology company that has yet to generate any revenue or earnings. The company’s public filings confirm that it has no product currently available to the market, and its valuation is driven entirely by the potential of its obesity‑drug pipeline.
The centerpiece of Viking’s pipeline is VK2735, a dual agonist of the GLP‑1 and GIP receptors. According to a report on Investing.com, the company presented data from a 13‑week Phase 2 trial of oral VK2735 at the European Congress on Obesity on May 12, 2026. The trial showed an average weight loss of up to 12.2 % in participants, with no plateau observed during the study period. The results were also highlighted by a Motley Fool article that noted the drug’s performance and the company’s “strong pipeline.” Despite these encouraging data, VK2735 has not yet received regulatory approval and is still in the clinical development stage.
Viking’s broader strategy includes plans to file an investigational new drug application for a dual amylin and calcitonin receptor agonist (DACRA) later in 2026. The company’s website states that its research and development activities focus on metabolic and endocrine disorders, positioning VK2735 within a competitive field that already includes established players such as Eli Lilly’s tirzepatide and Novo Nordisk’s semaglutide.
In addition to VK2735, Viking is advancing two other candidates. VK2809, a thyromimetic prodrug selective for the THR‑β isoform, is in a Phase II trial for non‑alcoholic steatohepatitis (NASH). The company also continues development of LGD‑4033, a selective androgen receptor modulator (SARM) under investigation for muscle atrophy in patients with hip fracture. Both programs are still in early clinical stages and have not yet produced revenue.
Viking’s financial position is modest. As of the latest market data, the stock trades around $31.27 per share with a trading volume of roughly 1.5 million shares. The company’s market capitalization is less than $4 billion. A recent investment of $7.25 million from ACT Capital Management was reported by Market Pulse, providing additional capital for the company’s ongoing trials.
The company’s lack of revenue and the speculative nature of its valuation have drawn cautious commentary from investors. Analysts note that while the Phase 2 data for VK2735 are promising, the obesity‑drug market is crowded and consumer acceptance of a new oral therapy remains uncertain. The company’s competitors have already secured regulatory approval and established market presence, giving them a head start.
Viking also faced a legal challenge in 2023 when it filed a lawsuit against Chinese developer Ascletis BioScience. The suit alleged that Ascletis had stolen trade secrets related to a compound similar to Viking’s VK2809. The lawsuit was reported in the context of the broader competitive landscape for thyroid‑related therapeutics.
In summary, Viking Therapeutics is a biotech firm with a focused pipeline in metabolic disorders but no current revenue or approved product. Its flagship obesity candidate, VK2735, has shown encouraging Phase 2 results but still requires regulatory approval and market acceptance. The company’s valuation remains speculative, and investors are watching the progression of its clinical programs and the competitive dynamics of the obesity‑drug market.
The next key milestones for Viking include the filing of an IND for DACRA, the completion of the Phase 2 trial for VK2735, and the ongoing development of VK2809 and LGD‑4033. Investors will also be monitoring the company’s financial statements, which are expected to remain negative until a product reaches the market.
The centerpiece of Viking’s pipeline is VK2735, a dual agonist of the GLP‑1 and GIP receptors. According to a report on Investing.com, the company presented data from a 13‑week Phase 2 trial of oral VK2735 at the European Congress on Obesity on May 12, 2026. The trial showed an average weight loss of up to 12.2 % in participants, with no plateau observed during the study period. The results were also highlighted by a Motley Fool article that noted the drug’s performance and the company’s “strong pipeline.” Despite these encouraging data, VK2735 has not yet received regulatory approval and is still in the clinical development stage.
Viking’s broader strategy includes plans to file an investigational new drug application for a dual amylin and calcitonin receptor agonist (DACRA) later in 2026. The company’s website states that its research and development activities focus on metabolic and endocrine disorders, positioning VK2735 within a competitive field that already includes established players such as Eli Lilly’s tirzepatide and Novo Nordisk’s semaglutide.
In addition to VK2735, Viking is advancing two other candidates. VK2809, a thyromimetic prodrug selective for the THR‑β isoform, is in a Phase II trial for non‑alcoholic steatohepatitis (NASH). The company also continues development of LGD‑4033, a selective androgen receptor modulator (SARM) under investigation for muscle atrophy in patients with hip fracture. Both programs are still in early clinical stages and have not yet produced revenue.
Viking’s financial position is modest. As of the latest market data, the stock trades around $31.27 per share with a trading volume of roughly 1.5 million shares. The company’s market capitalization is less than $4 billion. A recent investment of $7.25 million from ACT Capital Management was reported by Market Pulse, providing additional capital for the company’s ongoing trials.
The company’s lack of revenue and the speculative nature of its valuation have drawn cautious commentary from investors. Analysts note that while the Phase 2 data for VK2735 are promising, the obesity‑drug market is crowded and consumer acceptance of a new oral therapy remains uncertain. The company’s competitors have already secured regulatory approval and established market presence, giving them a head start.
Viking also faced a legal challenge in 2023 when it filed a lawsuit against Chinese developer Ascletis BioScience. The suit alleged that Ascletis had stolen trade secrets related to a compound similar to Viking’s VK2809. The lawsuit was reported in the context of the broader competitive landscape for thyroid‑related therapeutics.
In summary, Viking Therapeutics is a biotech firm with a focused pipeline in metabolic disorders but no current revenue or approved product. Its flagship obesity candidate, VK2735, has shown encouraging Phase 2 results but still requires regulatory approval and market acceptance. The company’s valuation remains speculative, and investors are watching the progression of its clinical programs and the competitive dynamics of the obesity‑drug market.
The next key milestones for Viking include the filing of an IND for DACRA, the completion of the Phase 2 trial for VK2735, and the ongoing development of VK2809 and LGD‑4033. Investors will also be monitoring the company’s financial statements, which are expected to remain negative until a product reaches the market.
